PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Funding withdrawn

Conditions

Stroke
Intracranial Atherosclerosis
Intraplaque Hemorrhage

Interventions

DRUG: Alirocumab
DRUG: Placebo

Sponsor

University of Utah

Collaborators

[object Object]